Skip to main content

Table 5 Multiple logistic regression analysis for high cost MASLD individuals

From: Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort

Risk factor

Adjusted odds ratio (95% CI)

High cost in 2018 (ref: non high cost in 2018)

5.80 (4.80–7.03)

BMI

1.04 (1.02–1.06)

Charlson Comorbidity Index score

1.29 (1.20–1.38)

Metabolic comorbidities

1.47 (1.22–1.78)

Cardiovascular diseases and stroke

1.59 (1.25–2.03)

Respiratory disease

1.48 (1.10–1.98)

Chronic inflammatory disease

4.12 (2.75–6.19)

Mental health disorders

1.77 (1.43–2.20)